Anixa Biosciences, Inc.
NASDAQ:ANIXBiotechnology
Healthcare
$2.71 +3.72%
+$0.10 today
- Market cap
- $94.21M
- Beta
- 0.60
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$0.30
52W Low $2.32High $5.46
Volume 0.29M
Average 0.12M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$11.70M
FY 2025 · Annual
Net Income
-$10.93M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Revenue | 512K | 0 | 210K | 0 | 0 |
| Cost of Revenue | 385K | 0 | 161K | 0 | 36K |
| Gross Profit | 127K | 0 | 49K | 0 | (36K) |
| Gross Margin | 24.8% | — | 23.3% | — | — |
| Research & Development | 6.19M | 6.7M | 4.77M | 6.4M | 5.07M |
| Selling, General & Admin | 7.07M | 7.17M | 6.29M | 7.44M | 6.63M |
| Operating Expenses | 13.26M | 13.88M | 11.06M | 13.83M | 11.67M |
| Depreciation & Amortization | 59.86K | 42K | 46K | 37K | 36K |
| EBITDA | (13.08M) | (13.73M) | (9.88M) | (12.66M) | (10.99M) |
| EBITDA Margin | -2554.9% | — | -4706.7% | — | — |
| Operating Income | (13.14M) | (13.88M) | (11.01M) | (13.83M) | (11.7M) |
| Operating Margin | -2565.6% | — | -5243.3% | — | — |
| Interest Income | 2.32K | 104K | 1.08M | 1.13M | 673K |
| Interest Expense | 322 | 104K | 0 | 0 | 0 |
| Other Income / Expenses | 7.77K | 104K | 1.08M | 1.13M | 673K |
| Income Before Tax | (13.13M) | (13.77M) | (9.93M) | (12.7M) | (11.03M) |
| Pre-Tax Margin | -2564.0% | — | -4728.6% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (12.95M) | (13.6M) | (9.81M) | (12.55M) | (10.93M) |
| Net Margin | -2528.6% | — | -4671.9% | — | — |
| EPS (Basic) | (0.45) | (0.45) | (0.32) | (0.39) | (0.34) |
| EPS (Diluted) | (0.45) | (0.45) | (0.32) | (0.39) | (0.34) |
| 28.58M | 30.37M | 30.98M | 31.9M | 32.45M | |
| 28.58M | 30.37M | 30.98M | 31.9M | 32.45M |
ANIX Earnings Waterfall · TTM
NASDAQ:ANIX · Revenue to Net Income
Key Ratios
EPS$-0.30
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-10.8
P/S Ratio0.0
Analysis
$0 of revenue converted into -$10.1M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.30, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 26, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 22, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 30, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 28, 2026 |
How much revenue does ANIX generate?
Anixa Biosciences, Inc. (ANIX) reported $0.00 of revenue in fiscal 2025.
Is ANIX profitable?
Anixa Biosciences, Inc. (ANIX) reported -$10.93M of net income.
Continue the stock analysis
Jump to another research area for this company.